Apotex Pays Out Over US Price-Fixing Claims
Deal Over Pravastatin Includes $24.1m Fine And Deferred Prosecution Agreement
Apotex has agreed to pay a $24.1m fine and enter into a deferred prosecution agreement to resolve US price-fixing claims over the cholesterol-lowering drug pravastatin.
You may also be interested in...
Three civil settlements worth more than $447m in total have been reached with the US Department of Justice by Sandoz, Apotex and Sun’s Taro to resolve allegations over price-fixing. The deals follow criminal penalties previously paid by the three companies.
Teva has struck a $950,000 deal to settle US price-fixing litigation with the state of Mississippi, in what the firm anticipates could be the first of multiple settlements with individual US states.
Fresh details have been revealed in the ongoing saga of US generic price-fixing litigation, with a newly-published unredacted complaint disclosing excerpts from a notebook alleged to contain details of anti-competitive conduct.